These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38833750)

  • 1. A consensus reverse docking approach for identification of a competitive inhibitor of acetyltransferase enhanced intracellular survival protein from Mycobacterium tuberculosis.
    Santos-Júnior PFDS; Batista VM; Nascimento IJDS; Nunes IC; Silva LR; Costa CACB; Freitas JD; Quintans-Júnior LJ; Araújo-Júnior JX; Freitas MEG; Zhan P; Green KD; Garneau-Tsodikova S; Mendonça-Júnior FJB; Rodrigues-Junior VS; Silva-Júnior EFD
    Bioorg Med Chem; 2024 Jun; 108():117774. PubMed ID: 38833750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
    Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Guided Optimization of Inhibitors of Acetyltransferase Eis from
    Punetha A; Ngo HX; Holbrook SYL; Green KD; Willby MJ; Bonnett SA; Krieger K; Dennis EK; Posey JE; Parish T; Tsodikov OV; Garneau-Tsodikova S
    ACS Chem Biol; 2020 Jun; 15(6):1581-1594. PubMed ID: 32421305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combating Enhanced Intracellular Survival (Eis)-Mediated Kanamycin Resistance of Mycobacterium tuberculosis by Novel Pyrrolo[1,5-a]pyrazine-Based Eis Inhibitors.
    Garzan A; Willby MJ; Ngo HX; Gajadeera CS; Green KD; Holbrook SY; Hou C; Posey JE; Tsodikov OV; Garneau-Tsodikova S
    ACS Infect Dis; 2017 Apr; 3(4):302-309. PubMed ID: 28192916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of Antitubercular Compound Library Identifies Inhibitors of Mur Enzymes in
    Eniyan K; Rani J; Ramachandran S; Bhat R; Khan IA; Bajpai U
    SLAS Discov; 2020 Jan; 25(1):70-78. PubMed ID: 31597510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Mycobacterium tuberculosis CtpF as a target for designing new antituberculous compounds.
    Santos P; Lopez-Vallejo F; Ramírez D; Caballero J; Mata Espinosa D; Hernández-Pando R; Soto CY
    Bioorg Med Chem; 2020 Feb; 28(3):115256. PubMed ID: 31879181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing the Robustness of Inhibitors of Tuberculosis Aminoglycoside Resistance Enzyme Eis by Mutagenesis.
    Green KD; Punetha A; Hou C; Garneau-Tsodikova S; Tsodikov OV
    ACS Infect Dis; 2019 Oct; 5(10):1772-1778. PubMed ID: 31433614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Inhibitory Effect of GlmU Acetyltransferase Inhibitor TPSA on
    Chen C; Han X; Yan Q; Wang C; Jia L; Taj A; Zhao L; Ma Y
    Front Cell Infect Microbiol; 2019; 9():251. PubMed ID: 31380295
    [No Abstract]   [Full Text] [Related]  

  • 10. Andrographolide: A potent antituberculosis compound that targets Aminoglycoside 2'-N-acetyltransferase in Mycobacterium tuberculosis.
    Prabu A; Hassan S; Prabuseenivasan ; Shainaba AS; Hanna LE; Kumar V
    J Mol Graph Model; 2015 Sep; 61():133-40. PubMed ID: 26245695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico Design and Synthesis of Tetrahydropyrimidinones and Tetrahydropyrimidinethiones as Potential Thymidylate Kinase Inhibitors Exerting Anti-TB Activity Against
    Venugopala KN; Tratrat C; Pillay M; Chandrashekharappa S; Al-Attraqchi OHA; Aldhubiab BE; Attimarad M; Alwassil OI; Nair AB; Sreeharsha N; Venugopala R; Morsy MA; Haroun M; Kumalo HM; Odhav B; Mlisana K
    Drug Des Devel Ther; 2020; 14():1027-1039. PubMed ID: 32214795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of potent chemical antituberculosis agents targeting Mycobacterium tuberculosis acetohydroxyacid synthase.
    Jung IP; Ha NR; Lee SC; Ryoo SW; Yoon MY
    Int J Antimicrob Agents; 2016 Sep; 48(3):247-58. PubMed ID: 27451857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
    Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
    Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations.
    Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN
    Tuberculosis (Edinb); 2020 Mar; 121():101920. PubMed ID: 32279872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent Inhibitors of Acetyltransferase Eis Overcome Kanamycin Resistance in Mycobacterium tuberculosis.
    Willby MJ; Green KD; Gajadeera CS; Hou C; Tsodikov OV; Posey JE; Garneau-Tsodikova S
    ACS Chem Biol; 2016 Jun; 11(6):1639-46. PubMed ID: 27010218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies.
    Venugopala KN; Chandrashekharappa S; Deb PK; Al-Shar'i NA; Pillay M; Tiwari P; Chopra D; Borah P; Tamhaev R; Mourey L; Lherbet C; Aldhubiab BE; Tratrat C; Attimarad M; Nair AB; Sreeharsha N; Mailavaram RP; Venugopala R; Mohanlall V; Morsy MA
    Int J Biol Macromol; 2024 Aug; 274(Pt 2):133285. PubMed ID: 38925196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations.
    Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R
    J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of inhibitors of the aminoglycoside resistance acetyltransferase Eis from Mycobacterium tuberculosis.
    Green KD; Chen W; Garneau-Tsodikova S
    ChemMedChem; 2012 Jan; 7(1):73-7. PubMed ID: 21898832
    [No Abstract]   [Full Text] [Related]  

  • 19. Docking- and pharmacophore-based virtual screening for the identification of novel Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with a thiobarbiturate scaffold.
    Zhang D; Lin Y; Chen X; Zhao W; Chen D; Gao M; Wang Q; Wang B; Huang H; Lu Y; Lu Y
    Bioorg Chem; 2019 Apr; 85():229-239. PubMed ID: 30641319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies.
    Sriram D; Yogeeswari P; Senthilkumar P; Naidu G; Bhat P
    J Enzyme Inhib Med Chem; 2010 Dec; 25(6):765-72. PubMed ID: 20569083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.